Oppenheimer Downgrades Dyne Therapeutics to Perform
Oppenheimer has downgraded Dyne Therapeutics from Outperform to Perform, setting a price target of $15.
Stocks · News reference
HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32
HC Wainwright & Co. analyst Ananda Ghosh maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and lowers the price target from $50 to $32.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Dyne Therapeutics Continues To Expect Topline Data In Q1 2027 From The Achieve REC, With A Primary Endpoint Of Change From Baseline In vHOT At 6 Months, Intended To Support A Potential Submission For U.S. Accelerated Approval In Q3 2027
8-K filing — Dyne Therapeutics, Inc. (DYN)
Filed: 2026-09-29 AccNo: 0001818794-26-000009 Size: 10 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits